Using FAERS Data as a Proxy to Determine Medical Costs for TNF alpha Inhibitors

Using FAERS Data as a Proxy to Determine Medical Costs for TNF alpha InhibitorsFor full access to this free poster, please complete the form on the right side of this page.

Presented at the ISPOR conference in May 2017, this poster and abstract:

  • Pairs FAERS data with specific claims data to determine downstream medical costs of adverse events associated with TNFa Inhibitors Humira (adalimumab), Enbrel (etanercept), Cimzia (certolizumab pegol), Remicade (infliximab), Simponi (golimumab), and Simponi Aria (golimumab).
  • Uses Advera’s Evidex platform to validate a hypothesis that the reporting rate of pneumonia as an adverse event in FAERS would be similar to the incidence rate of pneumonia as an adverse event in the WEA Trust medical claims database
  • Concludes that higher incidence of pneumonia caused by certain TNF alpha inhibitors would result in higher downstream medical costs

Summary Conclusions:

  • Cimzia(certolizumab) was shown to have a statistically significant increased rate of pneumonia and downstream medical cost per dispense in claims data when compared to Humira(adalimumab) and Enbrel (etanercept).

  • FAERS data indicated that Cimzia(certolizumab) has higher reporting rates for pneumonia, an elevated reporting odds ratio (ROR), and higher downstream medical cost in FAERS data when compared to Humira(adalimumab) and Enbrel (etanercept).

  • The per dispense medical cost in the WEA Trust claims data correlated to Advera Health’s calculated downstream medical cost from FAERS data.

  • Based on these findings, WEA Trust will be working with providers to modulate TNF-αinhibitor prescriptions to lower cost and improve safety.

 

Please note: This is an independent analysis conducted by Advera Health, based upon data and insight generated by the analytical tools of Evidex and other pertinent information gathered at the time of publication. This analysis is not sponsored or influenced by any third party. The inclusion of a particular company, drug, adverse event, class or indication in this report is determined wholly by our quantitative signaling and analytic systems along with our qualitative analysis work.